Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Liabilities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Total Liabilities data on record, last reported at $306.6 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 6.95% year-over-year to $306.6 million; the TTM value through Dec 2025 reached $306.6 million, down 6.95%, while the annual FY2025 figure was $306.6 million, 6.95% down from the prior year.
  • Total Liabilities reached $306.6 million in Q4 2025 per FHTX's latest filing, up from $294.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $422.9 million in Q4 2021 and bottomed at $104.3 million in Q2 2021.
  • Average Total Liabilities over 5 years is $324.1 million, with a median of $347.7 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 297.15% in 2022, then fell 12.49% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $422.9 million in 2021, then dropped by 4.29% to $404.8 million in 2022, then fell by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then fell by 6.95% to $306.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $306.6 million in Q4 2025, $294.6 million in Q3 2025, and $302.9 million in Q2 2025.